All posts by imreal

Driving Successful Uptake of Medicines and Medical Innovations in Healthcare Delivery, Upcoming Webinar Hosted by Xtalks


Register for this webinar to learn more about how implementation science methods and research approaches can help provide the evidence needed to support the uptake, adoption and sustained use of new medicinal products and medical care innovations in a range of real-world contexts.

The market approval of a new therapy is no guarantee of market success. In fact, many new therapeutic breakthroughs and advanced medical technologies fall short in their promise to transform medical care and patient outcomes because of challenges in integrating them into real-world healthcare delivery. Implementation science is an emerging field that seeks to overcome those challenges. It focuses on understanding and addressing barriers and facilitators to the uptake of new healthcare innovations into the specific contexts in which they are to be used and selecting and implementing strategies to address those barriers.

Register for this webinar to learn more about how implementation science methods and research approaches can help provide the evidence needed to support the uptake, adoption and sustained use of new medicinal products and medical care innovations in a range of real-world contexts.

Join Dr. Meredith Smith, PhD, MPA, FISPE, Senior Director of Implementation Science, Evidera Inc., for the live webinar on Wednesday, June 28, 2023, at 10am EDT (4pm CEST/EU-Central).

For more information, or to register for this event, visit Implementation Science: Driving Successful Uptake of Medicines and Medical Innovations in Healthcare Delivery.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

A Cutting-Edge Legal Database for Regulated Financial Industries


The launch of Compliance Journal is an exciting opportunity to provide our institutional clients with a one-stop solution to legal and regulatory documents through an easy to use on-online portal.

Shipkevich PLLC, an institutional business and finance law firm, is thrilled to announce the launch of its innovative legal database, Compliance Journal. This state-of-the-art digital platform empowers subscribers with easy access to a wealth of legal and regulatory information, fostering enhanced efficiency and informed decision-making.

Compliance Journal serves as a dynamic resource for professionals and organizations operating in Shipkevich PLLC’s core practice areas. With a user-friendly interface, clients and subscribers can effortlessly navigate through a vast collection of regulatory statutes, enforcement actions, and agency advisory opinions, tailored specifically to regulated industries such as debt relief, credit repair, credit counseling, loan brokerage, money transmission, and cryptocurrency.

Key Features of Compliance Journal include:


  • Comprehensive Legal Database: Subscribers gain access to a vast array of related search criteria, all neatly organized on a single page. From state and federal statutes to various regulatory guides and enforcement actions, users can find everything they need at their fingertips.
  • Legislative Tracker: Stay up-to-date with relevant legislative activities impacting your industry. Compliance Journal’s one-of-a-kind legislative tracker ensures users are informed about the latest regulatory developments, enabling them to proactively adapt their strategies.
  • Timely Digest of News and Analysis: Compliance Journal provides a periodic digest of news, alerts, and original analysis centered on U.S. debt relief, loan brokerage, money transmission, and cryptocurrency regulation. Stay informed about industry trends, emerging issues, and potential opportunities.
  • Educational Resources: Access an extensive library of original webinars and educational materials from past events hosted by Shipkevich PLLC. Stay ahead of the curve with valuable insights and expert guidance.
  • Powerful Search Capabilities: Find precisely what you’re looking for with a broad range of search capabilities spanning multiple regulatory agencies. Compliance Journal streamlines the process of locating statutes, rules, state enforcement actions, speeches, press releases, reports, sample letters, regulatory guidance, and more.

Compliance Journal is poised to revolutionize the way professionals and organizations navigate the complex legal and regulatory landscape. By providing a comprehensive and technologically advanced platform, Shipkevich PLLC aims to empower subscribers to work more efficiently, mitigate risks, and make well-informed decisions. Felix Shipkevich, Principal of the firm, said, “The launch of Compliance Journal is an exciting opportunity to provide our institutional clients with a one-stop solution to legal and regulatory documents through an easy to use online portal. We are also proud to be a boutique firm with a Big Law reach. This truly unique platform is evidence of our boutique institutional firm’s dedication to the core practice areas in which we service our clients.”

“Shipkevich PLLC is proud to launch a revolutionary platform to help our clients evolve, as industry leaders, to easily navigate complex statutory schemes and guidance,” said Jessica Livingston, the Florida partner of Shipkevich PLLC. “Our innovative approach to compiling and consolidating massive amounts of content into a one-stop shop is sure to provide a legal launchpad to greater success and preventative measures for our clientele, a type of client support that is not found at other boutique firms such as ours.”

To find out more about Compliance Journal or to participate in a demo, please contact Felix Shipkevich at 212-252-3003, or fs@shipkevich.com.

About Shipkevich PLLC

Shipkevich PLLC, established in 2011, is a forward-thinking, boutique law practice with a team of world-class, diverse professionals relentlessly surpassing the outdated model of a traditional law firm. Shipkevich PLLC serves a diverse institutional client base, including corporations spanning more than 30 countries. With offices in New York, London, and Miami, Shipkevich PLLC offers legal expertise in institutional business and finance, capital markets, futures and derivatives, money transmission and payments, digital assets and cryptocurrencies, consumer finance, and lending transactions.

Share article on social media or email:

Non-Invasive Approaches to NAFLD/NASH Drug Development, Upcoming Webinar Hosted by Xtalks


Gain valuable knowledge about the latest NASH biomarkers and their practical applications in clinical settings.

This webinar will focus on non-invasive approaches to NAFLD/NASH drug development. During the webinar, speakers will provide updates on current and emerging NASH biomarkers, which are also anticipated to be important tools in clinical practice. The audience will learn how data generated from these biomarker tests can inform clinicians, identify treatment efficacy and lead to identification of new biomarker targets.

Join this informative webinar on non-invasive strategies for NAFLD/NASH drug development. Gain valuable knowledge about the latest NASH biomarkers and their practical applications in clinical settings.

Join Margery A. Connelly, PhD, MBA, FAHA, Strategic Director, Diagnostics R&D, Labcorp; Katherine T. Landschulz, PhD, Senior Director and Therapeutic Area Lead, Cardiovascular/Metabolic/Renal Disease, NAFLD/NASH, Neurodegenerative Diseases, Biomarker Solution Center, Labcorp; and Dr. Mohammad Shadab Siddiqui, MD, Associate Professor, Gastroenterology and Hepatology, Virginia Commonwealth University, for the live webinar on Tuesday, June 27, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Non-Invasive Approaches to NAFLD/NASH Drug Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

How to Increase Patient Engagement in Your Clinical Trials, Upcoming Webinar Hosted by Xtalks


Working in partnership with patients can ensure impactful clinical benefit of treatments that address important unmet patient needs prioritized from the patient’s perspective.

Engaging with patients – and their caregivers and advocates – during the planning and execution of clinical trials is crucial. When patients are involved in the clinical development plan and creation of the trial protocol and are encouraged to provide in-trial feedback, they are more likely to stay in the trial, understand their responsibilities, and adhere to the protocol requirements. Working in partnership with patients can ensure impactful clinical benefit of treatments that address important unmet patient needs prioritized from the patient’s perspective.

In recent years, pharma and MedTech companies have become much more conscious of the role of patients in product development, including the potential of including their input in the clinical research stage. Patient, caregiver, and advocate insights can help sponsors and researchers plan and execute accessible clinical trials with more feasible protocols, improved inclusion/exclusion criteria, and meaningful endpoints, ideally yielding completed trials with more impactful results while also saving time and financial resources.

However, lack of awareness, resources, and time to participate in patient engagement activities can negatively affect a company’s ability to benefit from patient input.

How do sponsors and researchers engage patients in the development lifecycle and make the most of their involvement in clinical trials?

In this webinar, our experts will review the range of tools that enable patient engagement during the clinical research stage of drug development.

The goal of every patient and their families is to have access to successful treatments that fully address their medical needs, with minimal invasion of their lives (time, pain, anxiety etc.). Therefore, patients should be working side by side with industry and regulators to make sure that new products indeed satisfy the above characteristics.

Join experts from Alira Health, Giulia Pierini (Moderator), Associate Director, Patient Engagement; Annabel de Maria, Chief Patient Officer; and Dr. Giacomo Basadonna, MD, Chief Medical Officer, Head of Global Medical Strategy, for the live webinar on Wednesday, June 28, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit How to Increase Patient Engagement in Your Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

The DRIPBaR Launches Newest Franchise in Gahanna, OH on June 19th, 2023


To celebrate their arrival, The DRIPBaR Gahanna-New Albany is offering 50% off any IV drip as well as a FREE B12 Quick Shot when you book before opening day, June 19th!

The DRIPBaR is excited to announce the opening of its newest location in Gahanna-New Albany on June 19th, 2023. This marks the newest location for the franchise, with approximately 600+ additional locations in the pipeline.

The DRIPBaR Gahanna-New Albany will offer all of the popular DRIPBaR IV vitamin therapy services, including IV drips and IM shots. This IV bar is owned and operated by Rebecca Ko and Carmen Snyder, who both have backgrounds in the health and fitness industry. Rebecca is a nurse and has an extensive background in the healthcare industry in the CCU (Coronary Care Unit), CTICU (Cardio Thoracic ICU), and as an IV Nurse Specialist. Rebecca is passionate about preventative wellness and not only receives IV drips but also owns three Orangetheory Fitness establishments in the Columbus area. For nearly 5 years, Carmen has managed Rebecca’s Orangetheory in New Albany, and their partnership has been a great success. Rebecca asked Carmen to join her in her next business venture, bringing innovative IV therapy to the Gahanna and New Albany communities. They are eager to expand to more franchises in the future.

Customers can choose from a variety of IV Lifestyle and IV Health Support Drips, designed to help them look and feel their best. If you’re looking for an extra boost but don’t have time for a full vitamin infusion, try one of our IM Quick Shots – six varieties to choose from that give the body an immediate boost.To celebrate their arrival, The DRIPBaR Gahanna-New Albany is offering 50% off any IV drip as well as a FREE B12 Quick Shot when you book before opening day, June 19th! Appointments can be booked here!

About The DRIPBaR

Founded in 2016, The DRIPBaR is a nationwide franchise focused on helping people obtain their best physical and mental health using intravenous therapies. Through advances in cellular and biological science, The DRIPBaR helps clients fight the consequences of chronic illness, address the effects of aging, and achieve balanced wellness. With a focus on ever-evolving treatments and medical advancements, the franchise hopes to shorten the gap between concierge and treatment-based medicine. The DRIPBaR already has more than 600 additional locations in various stages of development across 28 states, with over 50 currently open and operating. For more information, visit their website.

The DRIPBR Gahanna-New Albany

1352 N Hamilton Rd | Gahanna, OH 43230

(380) 234-3882

columbus204@thedripbar.com

https://www.thedripbar.com/gahanna/

Share article on social media or email:

Lybbie teams with Nest Collaborative to give parents easy access to telehealth breastfeeding support through their phone


Nest Collaborative now accessible via the Lybbie app

Lybbie users can now get same-day breastfeeding support from Nest Collaborative’s IBCLCs

“While breastfeeding is a natural process, that doesn’t mean it’s necessarily easy or intuitive. The goal of this partnership is to provide crucial preventive knowhow, skills and resources for every parent before they run into problems, not afterwards.”

Lybbie, the world’s first personal lactation training app, and Nest Collaborative, the nation’s first and largest virtual lactation consultation platform, announced a partnership to guide parents through the breastfeeding and parenting journey by providing same-day telehealth access to Nest Collaborative’s nationwide network of International Board-Certified Lactation Consultants (IBCLCs) directly through the Lybbie app.

The American Academy of Pediatrics recommends exclusively breastfeeding newborns for at least six months and up to two years, yet parents face many barriers to successful long-term breastfeeding, including a lack of prenatal education and poor access to clinical lactation support. According to the Centers for Disease Control and Prevention (CDC), 70% of parents who exclusively breastfeed their infant stop before the recommended six months.

The partnership between Lybbie and Nest Collaborative will make it easier for parents to start and maintain breastfeeding by providing them access to professional support and best practices directly through the Lybbie app on their phones. Lybbie users can simply click a button in the app to schedule a same-day or later appointment with a Nest Collaborative IBCLC.

“We’re excited to partner with Nest Collaborative and expand access to premium lactation support services for Lybbie users,” said Andrea Braden, MD, CEO and Co-Founder of Lybbie. “While breastfeeding is a natural process, that doesn’t mean it’s necessarily easy or intuitive. The goal of this partnership is to provide crucial preventive knowhow, skills and resources for every parent before they run into problems, not afterwards.”

“The preponderance of medical evidence shows that breastfeeding can improve the health of both parents and children, yet many parents lack easy, affordable access to professional lactation support,” said Judith Nowlin, CEO of Nest Collaborative, who was recently named to the Titan 100, a national recognition program for CEOs and C-level executives. “We’re excited to collaborate with Lybbie to help solve that problem and deliver a preventive model of care for breastfeeding parents who use the app.”

Nest Collaborative provides virtual support and evidence-based resources that address common concerns among parents ranging from prenatal planning for breastfeeding to balancing life with breastfeeding and pumping tutorials. Nest Collaborative’s IBCLCs are available for same-day appointments in all 50 states and multiple languages, without copay, out-of-pocket costs, or deductibles for families with active insurance coverage. Now, families will be able to quickly book appointments and have direct access to Nest Collaborative IBCLCs right through the Lybbie app.

Nest’s team of highly skilled IBCLCs, considered the gold standard in lactation care, work with families to meet their breastfeeding goals and resolve any concerns that may arise.

About Lybbie:

Lybbie is a multi-faceted technology platform that prioritizes the overall health of mom and baby to support the development and stability of a healthy milk supply. Lybbie created the world’s first smart breast-pumping bra (patent published) and the only mobile application designed to prevent and correct low milk supply. Lybbie’s mom-first mentality is innovating the current state of lactation care, empowering mothers and improving the breastfeeding experience for all. Company Founder Andrea Braden, a board-certified OB-GYN and a winner of the American Medical Association’s Inspiration Award, created Lybbie in response to her own struggles with breastfeeding. Download the Lybbie app today on the App Store or Google Play.

About Nest Collaborative:

Nest Collaborative, Farmington, CT, is the creator of the nation’s first virtual lactation platform. The company’s nationwide network of lactation consultants is available to families for same-day virtual consults, meaning more parents and their health providers have access to the help that creates successful breastfeeding journeys. Nest Collaborative was recognized by Verywell Family as the Best Online Lactation Consultant of 2021 and 2022, beating out competitors by offering insurance-covered appointments, same-day availability, and group sessions through their offering of Latch Lounge. For more information, visit https://www.nestcollaborative.com.

Share article on social media or email:

Helping Adults With Feeding or Swallowing Disorders


With an estimated one in six adults experiencing swallowing difficulties, the American Speech-Language-Hearing Association (ASHA) is encouraging the public to learn more about swallowing disorders (called dysphagia) and how to better support people who need help eating and drinking safely. This is a timely message—June is recognized as National Dysphagia Awareness Month.

Dysphagia can result from various causes. These include damage to the brain or nerves (from injuries or diseases including stroke, multiple sclerosis, or Parkinson’s disease); problems with the head, neck, or mouth (e.g., from cancer in the mouth, throat, or esophagus); or for other reasons such as medications that cause dry mouth.

Swallowing problems can lead to other medical issues such as dehydration, pneumonia, and aspiration (food going into the airway) as well as social isolation if a person withdraws from eating with others. For these reasons and more, it’s critical that people talk to their doctor if they suspect a swallowing problem. Ask for a referral to a speech-language pathologist (SLP)—a professional who diagnoses and treats dysphagia.

Help from caregivers, companions, and loved ones is key to recovery or successful management of dysphagia. Here are meaningful ways to assist a person with swallowing difficulties:

1. Provide support. Whether a person needs encouragement to seek help or is having a tough time with the treatment and recovery process, support from others is crucial.

2. Be an advocate. Accompany the person to their swallowing evaluation and follow-up appointments. Help them deal with insurance issues and paperwork. Ask questions of the doctor and/or SLP to understand the problem and treatment recommendations.

3. Prepare food. If treatment involves a modified diet, help prepare food or liquid to the recommended textures. An SLP will advise about what food and drink a person should consume.

4. Help them with muscle movement exercises. Exercises to improve muscle movement are often part of dysphagia treatment, and an SLP should recommend these exercises. Help the person with their exercises regularly.

5. Take notes. A person with dysphagia may need to track how much food or liquid they consume for their doctor or SLP. Help them keep a log of these details.

6. Show up. Because food and eating are often central to social situations, people with swallowing problems can retreat from participating and become very lonely. Visit them often, and help them find and attend social gatherings where food and eating are not involved.

For more information, and to find an ASHA-certified SLP (look for one that specializes in feeding and swallowing), visit https://www.asha.org/public/speech/swallowing/.

About the American Speech-Language-Hearing Association (ASHA)

ASHA is the national professional, scientific, and credentialing association for 228,000 members and affiliates who are audiologists; speech-language pathologists; speech, language, and hearing scientists; audiology and speech-language pathology support personnel; and students. Audiologists specialize in preventing and assessing hearing and balance disorders as well as providing audiologic treatment, including hearing aids. Speech-language pathologists (SLPs) identify, assess, and treat speech, language, and swallowing disorders. http://www.asha.org

Share article on social media or email:

Mount Sinai to Lead Discussions on Women’s Health, New Paths to Treat and Prevent Brain Disease, and Closing the Health Disparity Gap at the 2023 Aspen Ideas Festival


“We are proud to partner with the Aspen Institute to examine key issues that drive innovation and advance health, societal, and systemic changes for the global community,” said Kenneth L. Davis, MD, Chief Executive Officer of Mount Sinai Health System

Mount Sinai Health System experts will lead key discussions on women’s health, new paths to treat and prevent brain disease, and closing the gap on health disparities at this year’s Aspen Ideas: Health and Aspen Ideas Festival from Wednesday, June 21, to Friday, June 30, in Aspen, Colorado.

“We are proud to partner with the Aspen Institute to examine key issues that drive innovation and advance health, societal, and systemic changes for the global community,” said Kenneth L. Davis, MD, Chief Executive Officer of Mount Sinai Health System and Trustee of Aspen Institute. “The exchange of bold ideas that lead to sustainable solutions to the world’s most complex problems is one of the reasons we have sponsored the Aspen Ideas Festival for over 10 years.”

This year’s Aspen Ideas Festival will feature a range of experts who will share their ideas and insight. Built around festival themes that include the mind, artificial intelligence, energy innovation, and more, Mount Sinai’s conversations will broaden the understanding of health, science, and innovative thinkers who are moving medicine forward for the health of people everywhere. Mount Sinai is a Presenting Sponsor of the Aspen Ideas Festival and Aspen Ideas: Health, and the only underwriter to support both events. Please note that event time and location details are subject to change; visit our website http://www.mountsinai.org/aspen for the most up-to-date details.

Dr. Davis will appear on a panel on identifying diseases in the earliest stages utilizing new nanotechnology—the associated opportunities and risks–on Friday, June 23, at 2:50 pm MDT in the East Lawn Tent at Aspen Meadows. The panel will be moderated by Health Affairs’ Editor-in-Chief, Alan Weil. Health Affairs is the nation’s leading health policy journal.

Dr. Davis will also lead a conversation on new prevention strategies and treatments for brain disease on Sunday, June 25, at 3 pm MDT in the Booz Allen Hamilton Room at the Koch Building. He will be joined by Paul Kenny, PhD, Ward-Coleman Professor, and Chair, Nash Family Department of Neuroscience; Fanny Elahi, MD, PhD, Director, Fluid Biomarker Research, at the Icahn School of Medicine at Mount Sinai; and Ignacio Saez, PhD, Director, Human Neurophysiology Laboratory, at Icahn Mount Sinai.

Mount Sinai will host a panel discussion on women’s health that will be moderated by Monica Kraft, MD, Chair of the Mount Sinai Health System Department of Medicine. She will be joined by Elisa R. Port, MD, FACS, Chief, Breast Surgery, Mount Sinai Health System; Alan B. Copperman, MD, FACOG, Director, Reproductive Endocrinology and Infertility, Mount Sinai Health System; and Dolores Malaspina, MD, MS, MPH, Professor, Psychiatry, at Icahn Mount Sinai. This program will take place on Thursday, June 22, at 10:20 am MDT in the East Lawn Tent at Aspen Meadows.

Thomas Oxley, MBBS, PhD, BMedSc, FRACP, Director, Innovation Strategy, Mount Sinai Health System, will participate in a discussion on brain and computer interfaces on Wednesday, June 28, at 11:50 am MDT in the McNulty Room at the Doerr-Hosier Center.

Mount Sinai will host an executive luncheon talk on closing the gap on health disparities. Pamela Abner, MPA, CPXP, Vice President and Chief Diversity Operations Officer, Mount Sinai Health System, will moderate the roundtable and will be joined by Lynne Richardson, MD, FACEP, Co-Director, Institute for Health Equity Research, Icahn Mount Sinai, and Cardinale Smith, MD, PhD, Chief Medical Officer, Tisch Cancer Hospital at Mount Sinai. The roundtable will be held on Friday, June 23, at 12:15 pm MDT at Plato’s Restaurant in the Walter Isaacson Center at Aspen Meadows. This is a private event with limited capacity; please contact aspen@mountsinai.org for availability.

Mount Sinai clinicians will be onsite to provide complimentary full-body skin screenings and body scans with health and risk assessments. All of these offerings will be held at the Mount Sinai Health Experience, located in the Grove at Aspen Meadows. Sessions can be reserved in advance starting on Thursday, June 15, at aspen@mountsinai.org. For more information about Mount Sinai’s speakers, events, and activities at the Aspen Ideas: Health and Aspen Ideas Festival, visit our website at http://www.mountsinai.org/aspen.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

70% Of Major Pharmaceutical Companies And CROs Surveyed Have Adopted Digital Pathology


News Image

“The results of the 2023 Life Sciences Digital Pathology Adoption Survey confirms that digital pathology has earned its place on the C-suite agenda across life sciences organizations,” said David West, Proscia’s CEO

Nearly three-fourths of life sciences organizations surveyed have invested in digital pathology to advance drug research and development (R&D), according to new research commissioned by Proscia®. Over half of these organizations (53%) still center their operations around legacy software systems primarily for basic image viewing despite growing adoption of artificial intelligence (AI) to accelerate the introduction of breakthrough therapeutics.

The “2023 Life Sciences Digital Pathology Adoption Survey” asked 40 senior executives from top pharmaceutical companies and leading contract research organizations (CROs) about their use of digital pathology, the benefits it has delivered, and its future impacts. The results collectively indicate a growing need to unify teams, applications, including AI, and pathology data with a modern software platform that drives all stages of R&D across the connected enterprise.

Specific findings include:


  • Executives see digital pathology as a solution to R&D’s biggest challenges. The average drug takes 10 to 15 years and costs $2.6 billion to introduce to patients.[1] It follows that improving collaboration, which leads to added efficiency and eliminates the cost of shipping glass slides among today’s increasingly distributed research teams, and streamlining operations were cited as the top two reasons for going digital (83% of respondents). More generally, 80% of respondents see digital pathology as a means of overcoming lengthy timelines, and 68% view the technology as a way to cut costs.
  • AI is already powering drug discovery and development. 82% of respondents that use digital pathology have begun to implement AI. Among them, 87% leverage image analysis applications to unlock new insights, and 65% have deployed process automation solutions that drive quality and efficiency by reducing mundane tasks. All other current digital pathology users surveyed have plans to adopt AI. Combined, these findings highlight an intensifying need for an enterprise pathology platform that incorporates a broad portfolio of AI applications into routine operations.
  • Digital pathology is opening up a new data opportunity. 55% of respondents indicated that creating data assets is a key driver of their digital pathology investment. As pathology data informs every drug brought to market and each whole slide image contains over 1 billion pixels that can shape future breakthroughs, pharmaceutical leaders recognize the potential of this new source of real world data and should now consider how to fully incorporate it into their workflows.

“Our survey confirms that digital pathology has earned its place on the C-suite agenda across life sciences organizations,” said David West, Proscia’s CEO. “These executives see its promise and must now grow their implementations to realize its full potential today and in the future with modern software. As they do, we anticipate that the enterprise pathology platform will establish itself as a new standard for bringing innovative therapies to patients.”

The “2023 Life Sciences Digital Pathology Adoption Survey” was conducted by Atheneum on Proscia’s behalf. To read all of the findings, access the full report here.

About Proscia

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.

[1] Pharmaceutical Researchers and Manufacturers of America. (2021, September 30). Research & Development Policy Framework. PhRMA Org. Retrieved May 9, 2023, from https://phrma.org/policy-issues/Research-and-Development-Policy-Framework

Share article on social media or email:

A-Alpha Bio Announces Collaboration With Gilead to Advance Next-Generation HIV Therapeutic Options


We are excited to collaborate with Gilead to advance the next generation of HIV therapies, drawing on our expertise in discovering and optimizing highly cross-reactive biologics

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, today announced a collaboration with Gilead Sciences, Inc. (Gilead) that aims to advance the design of human immunodeficiency virus (HIV) therapies. A-Alpha Bio will leverage its platforms to characterize binding affinities between potential therapeutic proteins and various viral protein variants that Gilead may incorporate into potential future long-acting combination HIV therapy options.

Under the collaboration, A-Alpha will apply its synthetic biology platform, AlphaSeq, to assess millions of interactions between potential therapeutic moieties and viral protein variants. The data generated by AlphaSeq will inform their machine learning (ML) platform, AlphaBind, to predict proteins that offer enhanced binding breadth and resistance to viral escape. As part of the collaboration, A-Alpha Bio will receive upfront and near-term success payments and will be eligible for development milestones and royalties if Gilead exercises its option to license novel proteins identified by A-Alpha.

HIV remains a global epidemic despite monumental scientific advances. The urgent nature of the epidemic has led to the development and implementation of therapeutics targeting all phases of the viral life cycle. Research and innovation that focuses on the development of novel HIV therapeutics will have the most significant public health impact in expanding options for all people affected by HIV.

A-Alpha Bio, the protein-protein interaction company, is uniquely suited to discover and optimize biologics with challenging binding requirements, such as broad cross-reactivity. This advantage stems from their ability to measure protein-protein interactions at a library-on-library scale with their AlphaSeq platform and their ability to explore an enormous sequence space computationally with their AlphaBind platform. “We are excited to collaborate with Gilead to advance the next generation of HIV therapies, drawing on our expertise in discovering and optimizing highly cross-reactive biologics,” said David Younger, CEO and Co-founder of A-Alpha Bio. “Gilead is a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research for more than three decades. We are confident that the insights we aim to provide through our platforms will support Gilead’s continuous pursuit of scientific discovery to provide solutions for the evolving needs of people affected by HIV around the world.”

About A-Alpha Bio

A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.

The company’s AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company’s AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.

A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington’s Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/.

Share article on social media or email: